Inhibits ERK2 (Ki = 525nM). Also inhibits adenosine kinase (Ki = 30nM), CK1 and CK2 and insulin receptor kinase (IC50 ranging from 0.4-28µM).
Product Details
| Alternative Name: | 4-Amino-5-iodo-7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine |
| |
| Formula: | C11H13IN04 |
| |
| MW: | 392.1 |
| |
| CAS: | 24386-93-4 |
| |
| Purity: | ≥98% (TLC) |
| |
| Identity: | Determined by 1H-NMR and MS |
| |
| Appearance: | Off-white solid |
| |
| Solubility: | Soluble in DMSO (25mg/ml) or 100% ethanol (8mg/ml warm) |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase: T. Fox et al.; Protein. Sci.
7, 2249 (1998),
Abstract;
Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor: D. Massillon et al.; Biochem. J.
299 , 123 (1994),
Abstract;
